Allentown LLC Announces the Acquisition of ClorDiSys

Allentown a leading provider of life science solutions has acquired ClorDiSys to further expand Allentown’s footprint in the global biomedical research and life science markets.

Charles Simmons, CEO of Allentown stated…..

“In pursuing our strategy to provide a full spectrum of high-science equipment, consumables, and services to our trusted biomedical research customers and broadening our offerings and scientific services into adjacent life science industries, we’re thrilled when we find a leading organization that can help us pursue our goals. ClorDiSys is that type of company, offering innovative and effective decontamination solutions with integrity and care, perfectly aligned with our cause to improve science and lifesaving research.”

Dane Kmetz, Vice President of M&A and Business Development, added…

“Acquiring best-in-class companies with high-performing teams and customer-centric solutions continues to be the focal point of our growth strategy. We welcome ClorDiSys to the Allentown family and look forward to expanding the reach of their mission-critical products and services.”

ClorDiSys is a family-owned and operated company that began in 2001 as a decontamination equipment provider but quickly added surface-top disinfection products, as well as on-site decontamination services to its portfolio to better address customer challenges.

Since then, ClorDiSys has provided decontamination solutions to customers worldwide and across many industries, and much like Allentown’s path over the past 55 years, their commitment to customer satisfaction and quality has allowed them to become a market leader.

Paul Lorcheim, the Director and Co-Founder of ClorDiSys added…

“Being acquired by Allentown is exactly what we needed to broaden our reach and make our services available to many more research institutions and adjacent industries. We want to lead the world and be the catalyst of driving a better and healthier process and shift away from Ethylene Oxide (EtO) for medical device sterilization and into ClorDiSys’ chlorine dioxide gas sterilization technology. ClorDiSys is quickly expanding into the medical device sterilization market, tripling the number of locations utilizing our technology in the last year alone. Unlike EtO, our process is more efficient, non-carcinogenic, non-explosive, and greatly reduces the impact on the environment.”

With the acquisition of ClorDiSys Allentown will add decontamination, disinfection, and sterilization services to its solution offerings. This new capability will help close the loop on crucial vivarium services already provided by Allentown, allowing for the decontamination and recommissioning of essential research equipment back into service. This holistic approach will offer customers peace of mind and ease of interaction with one solutions provider, consolidating customer procurement processes and increasing the number of innovative solutions Allentown offers.

This acquisition is also in line with Allentown’s commitment to innovation and an expansion of scientific service offerings for the vivarium and broader life science markets.

 

SourceAllentown

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”